Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks.

The study aims to evaluate the short-term and long-term efficacy and safety of Belimumab in adults with early systemic lupus erythematosus (SLE) who have ongoing disease activity despite stable ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks.

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control ...

BARCELONA, Spain — Monitoring blood hydroxychloroquine levels could help to ensure that patients with systemic lupus erythematosus (SLE) are being treated with the drug optimally, according to ...

Systemic lupus erythematosus, a.k.a. lupus, is a chronic autoimmune condition that causes the immune system to attack healthy tissues and organs. It can affect the joints, skin, kidneys, blood ...

Leukemia and lupus are both conditions that affect the immune system. Although they are different, they share certain symptoms. A person with lupus may have increased risk of developing leukemia.

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has now ...

About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, ...

MANCHESTER, England — Two new randomized controlled trials (RCTs) assessing the role of rituximab in the treatment of various stages of systemic lupus erythematosus (SLE) have the green light to ...